Cargando…
Structural genomics of infectious disease drug targets: the SSGCID
The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium of researchers at Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory that was established to apply structural genomics approaches to drug targets from inf...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169389/ https://www.ncbi.nlm.nih.gov/pubmed/21904037 http://dx.doi.org/10.1107/S1744309111029204 |
_version_ | 1782211472703619072 |
---|---|
author | Stacy, Robin Begley, Darren W. Phan, Isabelle Staker, Bart L. Van Voorhis, Wesley C. Varani, Gabriele Buchko, Garry W. Stewart, Lance J. Myler, Peter J. |
author_facet | Stacy, Robin Begley, Darren W. Phan, Isabelle Staker, Bart L. Van Voorhis, Wesley C. Varani, Gabriele Buchko, Garry W. Stewart, Lance J. Myler, Peter J. |
author_sort | Stacy, Robin |
collection | PubMed |
description | The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium of researchers at Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory that was established to apply structural genomics approaches to drug targets from infectious disease organisms. The SSGCID is currently funded over a five-year period by the National Institute of Allergy and Infectious Diseases (NIAID) to determine the three-dimensional structures of 400 proteins from a variety of Category A, B and C pathogens. Target selection engages the infectious disease research and drug-therapy communities to identify drug targets, essential enzymes, virulence factors and vaccine candidates of biomedical relevance to combat infectious diseases. The protein-expression systems, purified proteins, ligand screens and three-dimensional structures produced by SSGCID constitute a valuable resource for drug-discovery research, all of which is made freely available to the greater scientific community. This issue of Acta Crystallographica Section F, entirely devoted to the work of the SSGCID, covers the details of the high-throughput pipeline and presents a series of structures from a broad array of pathogenic organisms. Here, a background is provided on the structural genomics of infectious disease, the essential components of the SSGCID pipeline are discussed and a survey of progress to date is presented. |
format | Online Article Text |
id | pubmed-3169389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | International Union of Crystallography |
record_format | MEDLINE/PubMed |
spelling | pubmed-31693892011-09-21 Structural genomics of infectious disease drug targets: the SSGCID Stacy, Robin Begley, Darren W. Phan, Isabelle Staker, Bart L. Van Voorhis, Wesley C. Varani, Gabriele Buchko, Garry W. Stewart, Lance J. Myler, Peter J. Acta Crystallogr Sect F Struct Biol Cryst Commun Introduction The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium of researchers at Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory that was established to apply structural genomics approaches to drug targets from infectious disease organisms. The SSGCID is currently funded over a five-year period by the National Institute of Allergy and Infectious Diseases (NIAID) to determine the three-dimensional structures of 400 proteins from a variety of Category A, B and C pathogens. Target selection engages the infectious disease research and drug-therapy communities to identify drug targets, essential enzymes, virulence factors and vaccine candidates of biomedical relevance to combat infectious diseases. The protein-expression systems, purified proteins, ligand screens and three-dimensional structures produced by SSGCID constitute a valuable resource for drug-discovery research, all of which is made freely available to the greater scientific community. This issue of Acta Crystallographica Section F, entirely devoted to the work of the SSGCID, covers the details of the high-throughput pipeline and presents a series of structures from a broad array of pathogenic organisms. Here, a background is provided on the structural genomics of infectious disease, the essential components of the SSGCID pipeline are discussed and a survey of progress to date is presented. International Union of Crystallography 2011-08-13 /pmc/articles/PMC3169389/ /pubmed/21904037 http://dx.doi.org/10.1107/S1744309111029204 Text en © Stacy et al. 2011 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited. |
spellingShingle | Introduction Stacy, Robin Begley, Darren W. Phan, Isabelle Staker, Bart L. Van Voorhis, Wesley C. Varani, Gabriele Buchko, Garry W. Stewart, Lance J. Myler, Peter J. Structural genomics of infectious disease drug targets: the SSGCID |
title | Structural genomics of infectious disease drug targets: the SSGCID |
title_full | Structural genomics of infectious disease drug targets: the SSGCID |
title_fullStr | Structural genomics of infectious disease drug targets: the SSGCID |
title_full_unstemmed | Structural genomics of infectious disease drug targets: the SSGCID |
title_short | Structural genomics of infectious disease drug targets: the SSGCID |
title_sort | structural genomics of infectious disease drug targets: the ssgcid |
topic | Introduction |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169389/ https://www.ncbi.nlm.nih.gov/pubmed/21904037 http://dx.doi.org/10.1107/S1744309111029204 |
work_keys_str_mv | AT stacyrobin structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT begleydarrenw structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT phanisabelle structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT stakerbartl structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT vanvoorhiswesleyc structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT varanigabriele structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT buchkogarryw structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT stewartlancej structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid AT mylerpeterj structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid |